NCT01004159View on ClinicalTrials.gov

Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Colorectal Cancer
Interventions
DRUG

cetuximab with irinotecan

Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER